Clinical Symptoms in Children vs Adults with Narcolepsy and Cataplexy
Obesity, night eating, parasomnia, sleep talking and drunkenness, and ADHD symptoms are more frequent in children than adults at narcolepsy diagnosis.
Narcolepsy
FDA Approves Xywav for Narcolepsy
The FDA has approved Xywav™ oral solution for the treatment of cataplexy or EDS in patients aged ≥7 years with narcolepsy.
Clinical Improvement Observed in Narcolepsy Trial Evaluating Once-Nightly Sodium Oxybate Formulation
Positive topline data from the phase 3 REST-ON trial evaluating FT218 (Avadel), an investigational, once-nightly formulation of sodium oxybate, showed that the treatment led to clinically meaningful improvement in patients with narcolepsy.
The Narcolepsy Severity Scale Is Valid, Reliable in Treatment of Narcolepsy
Researchers suggest the Narcolepsy Severity Scale be used more frequently in the clinical settings and future narcolepsy studies.
Lower Sodium Oxybate Formulation Gets Priority Review for Narcolepsy
The FDA has accepted for Priority Review the New Drug Application for JZP-258 for the treatment of cataplexy or excessive daytime sleepiness in patients aged ≥7 years with narcolepsy.
Factors Affecting Quality of Life in People With Narcolepsy: The PROMIS Measures
Depression, negative social stigma, and dissatisfaction with current clinical care can have an impact on health-related quality of life in patients with narcolepsy.
Solriamfetol Improves Several Quality of Life Markers in People With Narcolepsy
Solriamfetol offers short-term improvements in functional status, health-related quality of life, and work productivity in people with narcolepsy.
Sustained Improvement in Excessive Daytime Sleepiness for Patients With Narcolepsy on Pitolisant
Researchers find treatment with pitolisant is associated with reductions in excessive daytime sleepiness and cataplexy over a 1-year period in patients with narcolepsy.
Pitolisant Reduces Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy
Treatment with pitolisant, a potent and highly selective H3-receptor antagonist/inverse agonist, reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy.
FDA Approves Pitolisant for Excessive Daytime Sleepiness in Adults With Narcolepsy
Wakix is a selective H3 receptor antagonist/inverse agonist and the first treatment for narcolepsy that is not scheduled as a controlled substance.
-
Loading...
-
Loading...
Next post in Sleep Disorders
